Recombinant human erythropoietin for treating treatment-resistant depression: a double-blind, randomized, placebo-controlled phase 2 trial

    Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, Volume 39, Issue 6, 2014, Pages 1399-1408.

    Cited by: 54|Bibtex|Views0|Links
    WOS NATURE
    Keywords:
    psychopharmacology schizophrenia addiction disorders depression anxiety

    Abstract:

    Pharmacological treatments for depression have insufficient efficacy in 30-40% of patients and fail to reverse cognitive deficits. Erythropoietin (EPO) has neurotrophic actions and aids neurocognitive function. The aim of this exploratory study was to determine whether recombinant human EPO improves mood and memory in treatment-resistant ...More

    Code:

    Data:

    Your rating :
    0

     

    Tags
    Comments